髂静脉支架置入术改善慢性深静脉疾病患者生活质量
该回顾性单中心研究分析了2016至2019年间因慢性静脉流出道梗阻接受髂静脉支架置入术的187例患者,通过VEINES-QoL/Sym问卷和Villalta评分评估生活质量和疾病严重程度。结果显示术后各随访时间点VEINES-QoL/Sym评分显著改善,Villalta评分显著降低,且改善持续至36个月。
要点
- 髂静脉支架置入术后VEINES-QoL评分从基线35.69显著提高,并在36个月内持续改善。
- Villalta评分从基线14降至36个月时的6,显示血栓后综合征严重程度降低。
- 配对分析证实VEINES-QoL、VEINES-Sym和Villalta评分在6、12、24个月均显著改善。
核心结论
- 髂静脉支架置入术可改善慢性静脉流出道梗阻患者的静脉疾病特异性生活质量,并降低血栓后综合征严重程度,改善持续至36个月。
研究设计与样本
- 回顾性单中心分析,纳入2016至2019年间完成VEINES-QoL/Sym问卷的187例接受髂静脉支架置入术的患者,共385份问卷。
- 中位随访12个月,127例(68%)为女性,148例(79%)因血栓后综合征接受治疗。
主要发现
- 基线VEINES-QoL中位评分为35.69(IQR 20.85-46.67),术后6个月为64.81(IQR 38.12-83.88),12个月为60.52(IQR 33.6-82.3),24个月为60.37(IQR 34.31-80.65),36个月为55.98(IQR 39.18-81.47)。
- VEINES-Sym评分呈现类似改善。
- 配对分析(61例)显示VEINES-QoL在6个月增加26.45,12个月增加25.81,24个月增加30.09(P ≤ .0001);VEINES-Sym在6个月增加23.86,12个月增加20.43,24个月增加27.55(P > .001);Villalta评分在6个月降低3.7,12个月降低4.2,24个月降低6.4(P < .0001)。
- Villalta中位评分从基线14(IQR 10-16)降至6个月9(IQR 5-13)、12个月8(IQR 5-11)、24个月7(IQR 4-12)、36个月6(IQR 3.75-10.25)(P ≤ .0001)。
- 随访时Villalta与VEINES-QoL和VEINES-Sym评分均呈良好相关性(r = 0.69和r = 0.71,P < .0001)。
临床怎么用
- 对于慢性静脉流出道梗阻患者,髂静脉支架置入术可作为一种改善生活质量和降低血栓后综合征严重程度的治疗选择。
- 使用VEINES-QoL/Sym问卷和Villalta评分可在术前及术后随访中量化评估患者生活质量和疾病严重程度的变化。
局限性
- 本研究为回顾性单中心分析,可能存在选择偏倚。
- 配对分析仅纳入61例患者,样本量有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The objective of the study was to evaluate change in venous disease-specific quality of life (QoL) after iliac vein stenting for chronic venous outflow obstruction. METHODS: We performed a retrospective analysis of all Venous Insufficiency Epidemiological and Economic Study - Quality of Life/Symptoms (VEINES-QoL/Sym) questionnaires completed at a single-center between 2016 and 2019 by patients treated with iliac vein stenting for chronic venous outflow obstruction. Patients were asked to complete the questionnaire at baseline (before stenting) and at subsequent follow-up appointments (after stenting), at 6, 12, 24, and 36 months. The Villalta score was recorded by a venous nurse specialist. The initial unpaired analysis compared all completed VEINES-QoL/Sym and Villalta scores at baseline to all follow-up time-points, and then compared them individually between baseline and each follow-up point. A secondary paired analysis included data only from patients who had completed the questionnaire at baseline and at least one follow-up. RESULTS: A total of 385 questionnaires from 187 patients who completed the VEINES-QoL/Sym between 2016 and 2019 were included. The median follow-up was 12 months, 127 patients (68%) were female, and 148 (79%) were treated for post-thrombotic syndrome. The median VEINES-QoL score at baseline was 35.69 (interquartile range [IQR], 20.85-46.67). Significant improvement was observed postoperatively and sustained throughout the study period (6 months, 64.81 [IQR, 38.12-83.88]; 12 months, 60.52 [IQR, 33.6-82.3]; 24 months, 60.37 [IQR, 34.31-80.65]; 36 months, 55.98 [IQR, 39.18-81.47]). The VEINES-Sym scores demonstrated similar improvement. A secondary analysis of paired baseline/follow-up data from 61 patients confirmed significant improvement from baseline for VEINES-QoL (6 months +26.45; 12 months, +25.81; 24 months, +30.09; P ≤ .0001), VEINES-Sym (6 months, +23.86; 12 months, +20.43; 24 months, +27.55; P > .001), and Villalta scores (6 months, -3.7; 12 months, -4.2; 24 months, -6.4; P < .0001). The median Villalta score was 14 (IQR, 10-16). This score improved to 9 (IQR, 5-13) at 6 months of follow-up; to 8 (IQR, 5-11) at 12 months; to 7 (IQR, 4-12) at 24 months; and to 6 (IQR, 3.75-10.25) at 36 months (P ≤ .0001). Good correlation between the Villalta and both VEINES-QoL and SYM scores was observed at follow-up (r = 0.69 and r = 0.71, respectively; P < .0001). CONCLUSIONS: Venous disease-specific QoL improves and severity of post-thrombotic syndrome is decreased after iliac vein stenting for chronic venous outflow obstruction. These improvements are sustained at 36-month follow-up.
引用
- Morris RI, Pouncey AL, Quintana B, et al. Quality of life outcomes for patients undergoing venous stenting for chronic deep venous disease. J Vasc Surg Venous Lymphat Disord. 2021. PMID: 33540137. doi:10.1016/j.jvsv.2021.01.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。